Emcure Pharma IPO: Public Issue Subscribed 16x On Final Day; GMP Soars; Check Allotment & Listing Dates

Emcure Pharmaceuticals, a well-established player in the global pharmaceutical industry, has garnered significant investor interest with its recent initial public offering (IPO). As of 1:21 pm on July 5, the IPO was oversubscribed by an impressive 15.69 times, indicating strong demand across various investor segments.

Retail investors, non-institutional investors, and qualified institutional buyers (QIBs) have all shown considerable interest in Emcure's offering. Retail investors oversubscribed their portion by 5.54 times, and Non-institutional investors (NIIs) displayed even greater enthusiasm, oversubscribing by a remarkable 33.40 times. Meanwhile, the QIB segment, comprising large institutional players, oversubscribed 20.63 times.

According to data from the Bombay Stock Exchange (BSE), the IPO's subscription status on the second day was 4.98 times overall. The QIB segment saw a subscription rate of 1 time, while NIIs received a subscription of 13.67 times. Retail investors had a subscription rate of 3.43 times, and the employee category received 4.83 subscriptions.

On the first bidding day, July 3, the IPO had already attracted significant attention, with an overall subscription rate of 1.32 times. This early interest set the stage for the heightened activity observed on subsequent days.

Based in Pune, Emcure Pharmaceuticals is engaged in the research, development, manufacturing, and sale of pharmaceutical products across various therapeutic areas globally. The company has established a presence in the market, offering a wide range of products that cater to diverse medical needs.

The IPO is priced between Rs 960 and Rs 1,008 per share, with the bidding period concluding on July 5. The offering includes a fresh issue of Rs 800 crore and an offer for sale (OFS) by existing promoters and shareholders amounting to Rs 1,151 crore. The total issue size at the upper end of the price band is Rs 1,952 crore.

The selling shareholders in the OFS include names such as Satish Ramanlal Mehta, Sunil Rajanikant Mehta, Namita Vikas Thapar, and Samit Satish Mehta. Additionally, shares will be offloaded by Pushpa Rajnikant Mehta, Bhavana Satish Mehta, Kamini Sunil Mehta, Arunkumar Purshotamlal Khanna, Berjis Minoo Desai, Sonali Sanjay Mehta, and BC Investments IV.

The IPO is being managed by a group of book-running lead managers, including Axis Capital Limited, JP Morgan India Private Limited, Jefferies India Private Limited, and Kotak Mahindra Capital Company Limited. Link Intime India Private Ltd. serves as the registrar for the offering.

Emcure Pharmaceuticals' IPO has also made waves in the grey market, where the shares are trading at a premium of Rs 335, as reported by investorgain.com. This premium suggests that investors are willing to pay significantly more than the issue price, reflecting strong market confidence in the company.

Considering the upper end of the IPO price band (Rs 1,008) and the current grey market premium, the expected listing price is projected to be around Rs 1,343 per share. This represents a potential gain of 33.23%.

The overwhelming response to Emcure Pharmaceuticals' IPO reflects the positive sentiment prevailing in the market and the strong confidence investors have in the company. The diverse participation from retail investors, NIIs, and QIBs reflects the broad-based appeal and trust in Emcure's business model and growth trajectory. As the bidding period concludes today, all eyes will be on the listing day, with the grey market premium indicating a potentially strong debut.